Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

A new study from the Tippie College of Business finds that many drug prices actually drop after pharmaceutical company ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

Shares of Catalyst Pharmaceuticals (CPRX) have resumed trading and are higher after the company announced that the company and its licensor ...

EST Catalyst Pharmaceuticals (CPRX) reports settlement of Firdapse patent litigation with Teva (TEVA) Stay Ahead of the Market:Discover ...

As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" ...

The Tel Aviv Stock Exchange fell today. The Tel Aviv 35 Index fell 0.74% to 2,439.98 points; the Tel Aviv 125 Index fell 0.80% to 2,480.62 points; and the BlueTech Global Index fell 1.27% to 470.08 ...

Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...

The global brain health supplements market has experienced significant growth in recent years, driven by increasing consumer awareness about cognitive health and the rising prevalence of neurological ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.